LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.
Scientists have devised new types of chimeric antigen-receptor (CAR) T cells -- a type of cancer immunotherapy -- that can be switched on to varying degrees of intensity and then switched off on ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC (CX-2051) with ...
OCTOBER 21, 2024, NEW YORK – Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results